VeriSeq NIPT Solution v2 makes NGS-based noninvasive prenatal testing accessible to any lab, providing:
VeriSeq NIPT Solution v2 uses PCR-free, whole-genome sequencing to expand prenatal screening beyond aneuploidies 21, 18, and 13 to all rare autosomal aneuploidies (RAAs), sex chromosome aneuploidies (SCAs), and partial duplications and deletions ≥7 Mb for all autosomes. This enables the VeriSeq NIPT Solution v2 to detect anomalies that targeted assays miss and deliver more insights into the health of a pregnancy.
Extensive validation of the VeriSeq NIPT Solution v2 confirmed high concordance with clinical reference data and a low test failure rate of 1.2%. An efficient 3-step workflow allows sample to report in 26 hours.
Sample preparation is automated on the VeriSeq NIPT Microlab STAR system, optimized for use in the VeriSeq NIPT workflow.
|Nucleic Acid Type
Model: Nextseq 550
– Is the only sequencing system capable of deploying applications running sequencing and reading microarray biochips
– New generation DNA sequencing system using synthetic sequencing technology: Sequencing by Synthesis – SBS
– The whole process of gene sequencing is conducted on the surface of flow cells, convenient to use and easy to manipulate.